56°
Known as fusion guided biopsy, Valley-Mount Sinai Comprehensive Cancer Care now offers the UroNav Fusion Biopsy System to patients as an outpatient procedure.
“This targeted MRI/ultrasound biopsy is poised to become a new standard in prostate cancer screening,” said Dr. Howard Frey, medical director of The Urologic Oncology Center at Valley-Mount Sinai Comprehensive Cancer Care. “The advanced technology will help us to more accurately diagnosis prostate cancer, which is the most common cancer among men after skin cancer.”
Combining MRI data with biopsy images, the UroNav Fusion Biopsy System allows doctors to target suspicious areas in real time. This provides a more effective and precise prostate biopsy than ever before. “Prostate cancer can be hard to detect, because patients often do not have symptoms at the time of diagnosis," said Frey. "Deciding what to do about prostate cancer can be challenging. It is important to distinguish between aggressive, potentially lethal prostate tumors, and those that are indolent and not life-threatening.”
In a standard biopsy, tissue sampling is done via ultrasound, which is unable to target specific areas. This can pose an issue if the prostate is enlarged, as random sampling can miss an aggressive tumor and focus instead on an inconsequential, non-aggressive area that does not require treatment.
Fusion Biopsy greatly improves on this standard technique. First, a prostate MRI is obtained, and if a suspicious area is identified, the result is fused with the live prostate ultrasound providing a target to biopsy. As a result, a directed biopsy is obtained and can show an intermediate to aggressive cancer. These results are then utilized to help doctors and patients decide on an appropriate treatment method."
For more information on The Valley Hospital's Urologic Oncology Center, please call 201-634-5567.
